Nu Hoang

US Patent:

20200308162, Oct 1, 2020

Filed:

Jun 11, 2020

Appl. No.:

16/899422

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrane CA, US
Nu Hoang - Annapolis MD, US
Jane Chisholm - Baltimore MD, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

C07D 417/04

Abstract:

New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.

US Patent:

20190060474, Feb 28, 2019

Filed:

Oct 16, 2018

Appl. No.:

16/162158

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

A61K 47/59
C07D 513/04
C07D 495/04
C07D 403/06
C07C 69/73
A61K 47/60
A61K 47/54
A61K 47/55

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20180110864, Apr 26, 2018

Filed:

Dec 14, 2017

Appl. No.:

15/842684

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

C07D 513/04
C07D 495/04
C07D 403/06
C07C 69/73

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20180104350, Apr 19, 2018

Filed:

Dec 14, 2017

Appl. No.:

15/842712

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

A61K 47/54
A61K 47/60
C07C 69/73
C07D 495/04
C07D 513/04
C07D 403/06
A61K 47/55
A61K 47/59

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20180064823, Mar 8, 2018

Filed:

Oct 12, 2017

Appl. No.:

15/782749

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

C07D 513/04
C07D 495/04
C07D 403/06
C07C 69/73

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20180036416, Feb 8, 2018

Filed:

Oct 12, 2017

Appl. No.:

15/782744

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

C07D 513/04
C07D 403/06
C07C 69/73
C07D 495/04

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20180028673, Feb 1, 2018

Filed:

Oct 12, 2017

Appl. No.:

15/782755

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US
Emmett Cunningham - Hillsborough CA, US

Assignee:

Graybug Vision, Inc. - Redwood CIty CA

International Classification:

C07D 513/04
C07D 403/06
C07C 69/73
C07D 495/04

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

US Patent:

20170080092, Mar 23, 2017

Filed:

Sep 22, 2016

Appl. No.:

15/273686

Inventors:

- Redwood City CA, US
Ming Yang - Lutherville-Timonium MD, US
John G. Bauman - El Sobrante CA, US
Nu Hoang - Annapolis MD, US

Assignee:

Graybug Vision, Inc. - Redwood City CA

International Classification:

A61K 47/48
C07D 403/06
C07C 69/73
C07D 495/04
C07D 513/04

Abstract:

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.